Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda plus Avastin in HER2-negative metastatic breast cancer
NCT00121836Phase 4Completed
- Sponsor
- Roche
- Start
- Jun 2005
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Roche. Primary endpoint: Overall Survival at 505 days. Started Jun 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00121836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121836.